{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T18:55:06Z","timestamp":1773168906148,"version":"3.50.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T00:00:00Z","timestamp":1691020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T00:00:00Z","timestamp":1691020800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s40262-023-01286-8","type":"journal-article","created":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T17:01:59Z","timestamp":1691082119000},"page":"1413-1425","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Population Pharmacokinetic Analysis of Dorzagliatin in Healthy Subjects and Patients with Type 2 Diabetes Mellitus"],"prefix":"10.1007","volume":"62","author":[{"given":"Kun","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingge","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiayi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quanfei","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengyan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongyi","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6192-3752","authenticated-orcid":false,"given":"Fuxing","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,8,3]]},"reference":[{"issue":"18","key":"1286_CR1","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1007\/s40265-022-01813-0","volume":"82","author":"YY Syed","year":"2022","unstructured":"Syed YY. Dorzagliatin: first approval. Drugs. 2022;82(18):1745\u201350.","journal-title":"Drugs"},{"key":"1286_CR2","first-page":"1619","volume":"10","author":"H Xu","year":"2016","unstructured":"Xu H, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of novel glucokinase activator HMS5552: results from a first-in-human single ascending dose study. Drug Des Devel Ther. 2016;10:1619\u201326.","journal-title":"Drug Des Devel Ther"},{"issue":"5","key":"1286_CR3","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1038\/s41591-022-01803-5","volume":"28","author":"W Yang","year":"2022","unstructured":"Yang W, et al. Dorzagliatin add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial. Nat Med. 2022;28(5):974\u201381.","journal-title":"Nat Med"},{"issue":"8","key":"1286_CR4","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/S2213-8587(18)30105-0","volume":"6","author":"D Zhu","year":"2018","unstructured":"Zhu D, et al. Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Diabetes Endocrinol. 2018;6(8):627\u201336.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"1286_CR5","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1038\/s41591-022-01802-6","volume":"28","author":"D Zhu","year":"2022","unstructured":"Zhu D, et al. Dorzagliatin in drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial. Nat Med. 2022;28(5):965\u201373.","journal-title":"Nat Med"},{"issue":"9","key":"1286_CR6","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1111\/dom.13338","volume":"20","author":"XX Zhu","year":"2018","unstructured":"Zhu XX, et al. Dorzagliatin (HMS5552), a novel dual-acting glucokinase activator, improves glycaemic control and pancreatic beta-cell function in patients with type 2 diabetes: A 28-day treatment study using biomarker-guided patient selection. Diabetes Obes Metab. 2018;20(9):2113\u201320.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"1286_CR7","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1111\/cts.13174","volume":"15","author":"J Miao","year":"2022","unstructured":"Miao J, et al. Effect of renal impairment on the pharmacokinetics and safety of dorzagliatin, a novel dual-acting glucokinase activator. Clin Transl Sci. 2022;15(2):548\u201357.","journal-title":"Clin Transl Sci"},{"issue":"6","key":"1286_CR8","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/BF01060053","volume":"8","author":"LB Sheiner","year":"1980","unstructured":"Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data. J Pharmacokinet Biopharm. 1980;8(6):553\u201371.","journal-title":"J Pharmacokinet Biopharm"},{"issue":"5","key":"1286_CR9","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/BF01061030","volume":"9","author":"LB Sheiner","year":"1981","unstructured":"Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetic parameters II Biexponential model and experimental pharmacokinetic data. J Pharmacokinet Biopharm. 1981;9(5):635\u201351.","journal-title":"J Pharmacokinet Biopharm"},{"issue":"3","key":"1286_CR10","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/BF01061870","volume":"11","author":"LB Sheiner","year":"1983","unstructured":"Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: routine clinical pharmacokinetic data. J Pharmacokinet Biopharm. 1983;11(3):303\u201319.","journal-title":"J Pharmacokinet Biopharm"},{"issue":"2","key":"1286_CR11","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.cmpb.2003.11.003","volume":"75","author":"L Lindbom","year":"2004","unstructured":"Lindbom L, Ribbing J, Jonsson EN. Perl-speaks-NONMEM (PsN)\u2013a Perl module for NONMEM related programming. Comput Methods Programs Biomed. 2004;75(2):85\u201394.","journal-title":"Comput Methods Programs Biomed"},{"issue":"3","key":"1286_CR12","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.cmpb.2005.04.005","volume":"79","author":"L Lindbom","year":"2005","unstructured":"Lindbom L, Pihlgren P, Jonsson EN. PsN-Toolkit\u2013a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed. 2005;79(3):241\u201357.","journal-title":"Comput Methods Programs Biomed"},{"issue":"6","key":"1286_CR13","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1002\/j.1552-4604.1997.tb04326.x","volume":"37","author":"EI Ette","year":"1997","unstructured":"Ette EI. Stability and performance of a population pharmacokinetic model. J Clin Pharmacol. 1997;37(6):486\u201395.","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"1286_CR14","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, et al. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13(2):143\u201351.","journal-title":"AAPS J"},{"key":"1286_CR15","unstructured":"FDA, Guidance for Industry Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling. 2003. https:\/\/www.fda.gov\/media\/71311\/download. Accessed 01 July 2023."},{"key":"1286_CR16","unstructured":"FDA, Guidance for Industry Pharmacokinetics in patients with impaired renal function\u2014study design, data analysis, and impact on dosing and labeling. 2020. https:\/\/www.fda.gov\/media\/78573\/download. Accessed 01 July 2023."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-023-01286-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-023-01286-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-023-01286-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T08:27:15Z","timestamp":1695630435000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-023-01286-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,3]]},"references-count":16,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["1286"],"URL":"https:\/\/doi.org\/10.1007\/s40262-023-01286-8","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,3]]},"assertion":[{"value":"29 June 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Hua Medicine.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"K.W., F.X., and Z.S. have received research funding and served in consultant roles to Hua Medicine. L.F., J.Z., Q.Z., L.C., and F.T. are employees of Hua Medicine.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Individual trial protocols were approved by the Institutional Review Boards\/Ethics Committees of the study sites.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All participants gave written informed consent before participating in the respective studies.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The datasets generated during and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability Statement"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"K.W. wrote the manuscript. L.C. and F.T. conceptualized the research. L.F., J.Z., and Q.Z. performed the research. K.W., F.X., and Z.S. analyzed the data. All authors reviewed the key steps of the analysis, commented on intermediate versions of the manuscript, and read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}